Clinical trial
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
NCT00573443
Study timeline
Study start (unknown)2007-12-01Date precision: month
Registry last updated2017-04-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Pseudobulbar Affect (PBA)unresolved
Interventions
Sponsors & collaborators
Avanir Pharmaceuticalslead sponsor
Syneos Healthcollaborator
Mapped research locations
New YorkNew York, United States2PhiladelphiaPennsylvania, United States2San FranciscoCalifornia, United States2HoustonTexas, United States1BostonMassachusetts, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1MiamiFlorida, United States1San AntonioTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00573443 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.